Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2001-05-10
2004-01-06
Low, Christopher S. F. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S547000, C514S533000, C514S016700, C530S311000
Reexamination Certificate
active
06673839
ABSTRACT:
The present invention relates to pharmaceutical compositions with antitumour activity, containing as active ingredient one or more acylcarnitines optionally in combination with other substances with antitumour activity. In particular, the invention relates to pharmaceutical compositions with antitumour activity, containing as active ingredient L-acetylcarnitine optionally in combination with somatostatin. The invention further relates to the use of acylcarnitines, in particular L-acetylcarnitine, for the preparation of medicaments with antitumour activity. Carnitines (which herein means carnitine, as well as the acylderivatives, optical isomers and racemates thereof) are compounds naturally occurring in various organs and systems of a number of living species, both vegetables and animals. Such compounds are available in the synthetic form, and they are used in common clinical practice in the treatment of primary carnitine deficiency, senile dementia and peripheral neuropathies. The recommended dosage for use in humans is about 30/mg/kg/day.
More particularly, acylcarnitines show a number of therapeutical properties, in that they have immunomodulating, antibacterial, antifungal, antishock, antidyslipidemic activities. Furthermore, they have a remarkable antiviral activity.
It has now been surprisingly found that acylcarnitines have a remarkable antitumour activity.
It has, for example, been observed that acetylcarnitine (N,N,N,-trimethyl-&bgr;-acetoxy-butyrobetaine), of formula
mainly in its L form, has a strong antitumour activity, both in animals and in humans and can therefore be used, either alone or in combination with other antitumour medicaments, in the treatment of malignant tumours.
Pre-treatment with acylcarnitine, in particular with L-acetylcarnitine, has been found to prevent the thriving of transplanted neoplasms in the animals and the relapses of resected neoplasms in humans.
REFERENCES:
patent: 5504069 (1996-04-01), Bogden et al.
patent: 0 845 265 (1998-06-01), None
patent: 05-339148 (1993-12-01), None
patent: WO 97/05862 (1997-02-01), None
patent: WO 97/06788 (1997-02-01), None
patent: WO 97/34596 (1997-09-01), None
Fischer et al. Toxicology in Vitro 3, 195-199 (1989).*
W.D. Thomitzek et al., “Die Wirkung von Palmitoylcarnitin auf Atmung, Glykolyse und Wachstum von Ehrlich-Ascites-Tumorzellen”,Die naturwissenschaften, vol. 52, No. 23, Dec. 1965, pp 644-645.
W.D. Thomitzek et al., “Der Einfluss von Palmitoylcarnitin auf Ehrlich-Aszites-Tumorzellen in vitro und in vivo”,Acta Biol Med Ger, vol. 17, No. 2, 1966, pp 145-159.
G. Vescovi et al., “Modulation by palmitoyl-carnitine of calcium activated phospholipid-dependent protein kinase activity and inhibition of melanoma cell growth”,The British Journal of Dermatology, vol. 119, No. 2, 1988, pp 171-178.
Toshio Nakaki et al., “Inhibition by palmitoylcarnitine of adhesion and morphological change in HL-60 cells induced by 12-0-tetradecanoylphorbol-13-acetate”,Cancer Research, vol. 44, No. 5, pp. 1908-1912, (1984).
K. Satyamoorthy et al., “Inhibition of mouse skin tumor promotion by adriamycin and daunomycin in combination with verapamil or palmitoylcarnitine”,Cancer Letters, vol. 55, No. 2, pp 135-142 (1990).
B. Neri et al., “Differences between carnitine derivatives and coenzyme Q10 in preventing in vitro doxorubicin-related cardiac damages”,Onocology, vol. 45, No. 3, 1988, pp. 242-246.
D. Krier et al., “Inhibition of Tumor Growth by L Carnitine”,74th Annual Meeting of the American Society of Biological Chemists, vol. 42, o. 7, Jun. 1983.
Allegra Eugenia
Rapisarda Grazia
Scandurra Laura
Stivala Franca Maria
Kam Chih-Min
Low Christopher S. F.
Universita' Degli Studi di Catania
Young & Thompson
LandOfFree
Pharmaceutical compositions with antitumour activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions with antitumour activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions with antitumour activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3243989